Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

被引：0
|
作者：
Capehorn, Matthew
Catarig, Andrei-Mircea
Frenkel, Ofir
Hindsberger, Charlotte
Marre, Michel
Price, Hermione
Pratley, Richard E.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-647-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
647-P
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Yu, Miao
    Yuan, Guo Yue
    Zhang, Bin
    Wu, Hai Ya
    Lv, Xiao Feng
    DIABETES THERAPY, 2020, 11 (05) : 1147 - 1159
  • [42] Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
    Kim, J. S.
    Leung, W. K.
    Wu, D. C.
    Lindner, D.
    Fadeeva, O.
    Demuth, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S431 - S431
  • [43] Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial
    Benedikt, Martin
    Mangge, Harald
    Aziz, Faisal
    Curcic, Pero
    Pailer, Sabine
    Herrmann, Markus
    Kolesnik, Ewald
    Tripolt, Norbert J.
    Pferschy, Peter N.
    Wallner, Markus
    Zirlik, Andreas
    Sourij, Harald
    von Lewinski, Dirk
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [44] Impact of the SGLT2-inhibitor Empagliflozin on inflammatory biomarkers in acute coronary syndrome-a post-hoc analysis of the EMMY trial
    Curcic, P.
    Herrmann, M.
    Pailer, S.
    Mangge, H.
    Benedikt, M.
    von Lewinski, D.
    Aziz, F.
    Kolesnik, E.
    Tripolt, J. N.
    Pferschy, P.
    Wallner, M.
    Zirlik, A.
    Sourij, H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S361 - S361
  • [45] Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
    Martin Benedikt
    Harald Mangge
    Faisal Aziz
    Pero Curcic
    Sabine Pailer
    Markus Herrmann
    Ewald Kolesnik
    Norbert J. Tripolt
    Peter N. Pferschy
    Markus Wallner
    Andreas Zirlik
    Harald Sourij
    Dirk von Lewinski
    Cardiovascular Diabetology, 22
  • [46] Impact of the SGLT2-inhibitor Empagliflozin on inflammatory biomarkers in acute myocardial infarction-a post-hoc analysis of the EMMY trial
    Benedikt, M.
    Kolesnik, E.
    Wallner, M.
    Zirlik, A.
    Sourij, H.
    Tripolt, N.
    Aziz, F.
    Vonbank, A.
    Purkarthofer, D.
    Wester, S.
    Kopp, K.
    Nahler, A.
    von Lewinski, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S359 - S360
  • [47] Risk of Urogenital Infections in Patients with Type 2 Diabetes Initiating SGLT2i Versus GLP-1RA: A Danish Emulated Target Trial
    Ljungberg, Christine
    Kristensen, Frederik P. B.
    Dalager-Pedersen, Michael
    Vandenbroucke-Grauls, Christina
    Norgaard, Mette
    Thomsen, Reimar W. W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 46 - 46
  • [48] Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis
    Qin Zhang
    Siyuan Zhou
    Lijun Liu
    Diabetology & Metabolic Syndrome, 15
  • [49] Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis
    Teng, Yunjie
    Fan, Xue
    Yu, Rui
    Yang, Xiaoping
    BMC ENDOCRINE DISORDERS, 2024, 24 (01)
  • [50] Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis
    Zhang, Qin
    Zhou, Siyuan
    Liu, Lijun
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
12345